Business Context and Reporting Period
This Form 8-K was filed by Neuralstem, Inc. on December 8, 2015. The report addresses the publication of Phase 1b clinical trial data for the company's lead small molecule drug, NSI-189, in patients with major depressive disorder.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development milestones rather than financial performance.
Material Changes
The material event reported is the publication of Phase 1b data in the journal Molecular Psychiatry. The data indicates that NSI-189, a benzylpiperizine-aminiopyridine compound with neurogenic and synaptogenic mechanisms, was well tolerated for 28 days at escalating doses.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the clinical data publication. The filing does not contain specific financial guidance, updated outlooks, or detailed risk factors beyond the standard context of clinical trials. No unusual items or contingencies were disclosed in this specific report.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.01 for detailed dosing information.
- Review the published article in Molecular Psychiatry to confirm the specific safety and tolerability metrics.
- Check subsequent filings for any updates on Phase 2 trial initiation or regulatory interactions following this Phase 1b data.